Century Therapeutics, Inc. (IPSC)
NASDAQ: IPSC · Real-Time Price · USD
2.200
-0.050 (-2.22%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Century Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Cash & Equivalents | 61.85 | 58.44 | 47.32 | 84.27 | 56.45 | Upgrade
|
| Short-Term Investments | 55.26 | 130.85 | 125.41 | 231.23 | 166.43 | Upgrade
|
| Cash & Short-Term Investments | 117.11 | 189.29 | 172.74 | 315.5 | 222.88 | Upgrade
|
| Cash Growth | -38.13% | 9.58% | -45.25% | 41.56% | 194.22% | Upgrade
|
| Other Receivables | 0.67 | 1.52 | 2.24 | 0.78 | 0.25 | Upgrade
|
| Receivables | 0.67 | 1.52 | 2.24 | 0.78 | 0.25 | Upgrade
|
| Prepaid Expenses | 0.52 | 1.53 | 0.76 | 1.45 | 1.61 | Upgrade
|
| Restricted Cash | 0.8 | - | - | - | - | Upgrade
|
| Other Current Assets | 1.67 | 1.71 | 1.26 | 1.99 | 3.42 | Upgrade
|
| Total Current Assets | 120.77 | 194.05 | 176.99 | 319.72 | 228.15 | Upgrade
|
| Property, Plant & Equipment | 66.17 | 90.85 | 92.08 | 111.73 | 69.82 | Upgrade
|
| Long-Term Investments | - | 30.82 | 89.1 | 51.85 | 135.91 | Upgrade
|
| Other Intangible Assets | 34.2 | 34.2 | - | - | - | Upgrade
|
| Other Long-Term Assets | 2.57 | 3.3 | 2.52 | 3.24 | 3.49 | Upgrade
|
| Total Assets | 223.7 | 353.22 | 360.69 | 486.54 | 437.38 | Upgrade
|
| Accounts Payable | 4.77 | 3.08 | 2.74 | 5.45 | 7.6 | Upgrade
|
| Accrued Expenses | 8.35 | 12.59 | 8.64 | 9.37 | 5.43 | Upgrade
|
| Current Portion of Long-Term Debt | - | - | - | 6.5 | 1.04 | Upgrade
|
| Current Portion of Leases | 3.32 | 4.87 | 1.51 | 0.48 | 0.62 | Upgrade
|
| Current Unearned Revenue | - | 109.16 | 4.37 | 7.15 | - | Upgrade
|
| Other Current Liabilities | 3.78 | 0.08 | 0.58 | 0.87 | 0.98 | Upgrade
|
| Total Current Liabilities | 20.23 | 129.78 | 17.85 | 29.82 | 15.66 | Upgrade
|
| Long-Term Debt | - | - | - | 3.74 | 8.9 | Upgrade
|
| Long-Term Leases | 40.24 | 48.96 | 46.66 | 38.7 | 14.56 | Upgrade
|
| Long-Term Unearned Revenue | - | - | 111.38 | 110.83 | - | Upgrade
|
| Long-Term Deferred Tax Liabilities | 4.3 | 4.37 | - | - | - | Upgrade
|
| Other Long-Term Liabilities | - | 8.74 | 0.06 | 0.72 | 2.02 | Upgrade
|
| Total Liabilities | 64.77 | 191.85 | 175.94 | 183.81 | 41.14 | Upgrade
|
| Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Additional Paid-In Capital | 950.81 | 943.37 | 840.41 | 824.29 | 785.05 | Upgrade
|
| Retained Earnings | -791.92 | -782.34 | -655.77 | -519.1 | -388.17 | Upgrade
|
| Comprehensive Income & Other | 0.03 | 0.32 | 0.11 | -2.46 | -0.65 | Upgrade
|
| Total Common Equity | 158.94 | 161.36 | 184.75 | 302.74 | 396.24 | Upgrade
|
| Shareholders' Equity | 158.94 | 161.36 | 184.75 | 302.74 | 396.24 | Upgrade
|
| Total Liabilities & Equity | 223.7 | 353.22 | 360.69 | 486.54 | 437.38 | Upgrade
|
| Total Debt | 43.57 | 53.83 | 48.17 | 49.41 | 25.12 | Upgrade
|
| Net Cash (Debt) | 73.55 | 135.46 | 124.57 | 266.08 | 197.76 | Upgrade
|
| Net Cash Growth | -45.70% | 8.75% | -53.19% | 34.55% | 264.89% | Upgrade
|
| Net Cash Per Share | 0.85 | 1.72 | 2.10 | 4.61 | 6.11 | Upgrade
|
| Filing Date Shares Outstanding | 179.72 | 86.05 | 64.82 | 59.17 | 58.82 | Upgrade
|
| Total Common Shares Outstanding | 87.52 | 85.84 | 60.34 | 58.47 | 55.01 | Upgrade
|
| Working Capital | 100.54 | 64.27 | 159.15 | 289.9 | 212.5 | Upgrade
|
| Book Value Per Share | 1.82 | 1.88 | 3.06 | 5.18 | 7.20 | Upgrade
|
| Tangible Book Value | 124.74 | 127.16 | 184.75 | 302.74 | 396.24 | Upgrade
|
| Tangible Book Value Per Share | 1.43 | 1.48 | 3.06 | 5.18 | 7.20 | Upgrade
|
| Machinery | 33.92 | 33.61 | 30.66 | 30.36 | 19.47 | Upgrade
|
| Construction In Progress | 0.11 | 0.1 | 0.12 | 14 | 32.84 | Upgrade
|
| Leasehold Improvements | 61.65 | 61.58 | 60.86 | 48.95 | 8.37 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.